JNJ-5207852: Difference between revisions

Latest revision as of 03:58, 13 February 2025

JNJ-5207852[edit]

JNJ-5207852 is a chemical compound that acts as a potent and selective antagonist of the 5-HT2A receptor, a subtype of the serotonin receptor. It was developed by Johnson & Johnson for potential use in the treatment of various psychiatric disorders, including schizophrenia and depression.

Mechanism of Action[edit]

JNJ-5207852 functions primarily by blocking the activity of the 5-HT2A receptor. The 5-HT2A receptor is a G protein-coupled receptor (GPCR) that is activated by the neurotransmitter serotonin. By inhibiting this receptor, JNJ-5207852 can modulate the effects of serotonin in the brain, which is thought to be beneficial in treating disorders characterized by dysregulated serotonin signaling.

Pharmacological Properties[edit]

JNJ-5207852 is known for its high affinity and selectivity for the 5-HT2A receptor, which minimizes its interaction with other serotonin receptor subtypes. This selectivity is crucial for reducing potential side effects associated with non-specific serotonin receptor antagonism.

Potential Therapeutic Uses[edit]

The primary therapeutic interest in JNJ-5207852 lies in its potential to treat schizophrenia, a complex psychiatric disorder characterized by symptoms such as hallucinations, delusions, and cognitive impairments. By antagonizing the 5-HT2A receptor, JNJ-5207852 may help alleviate some of these symptoms.

Additionally, there is interest in exploring its use in treating major depressive disorder, where it may help improve mood and cognitive function by modulating serotonin pathways.

Research and Development[edit]

Research into JNJ-5207852 has primarily focused on its pharmacological profile and its effects in preclinical models of psychiatric disorders. Studies have demonstrated its efficacy in reducing symptoms associated with schizophrenia in animal models, paving the way for potential clinical trials in humans.

Related Pages[edit]

@@ Line 1: / Line 1: @@
+{{DISPLAYTITLE:JNJ-5207852}}
+== JNJ-5207852 ==
-'''JNJ-5207852''' is a [[histamine antagonist]] selective for the [[Histamine H3 receptor|H<sub>3</sub>]] subtype. It has [[stimulant]] and [[nootropic]] effects in animal studies,<ref name="pmid15466448">{{cite journal |author=Barbier AJ, Berridge C, Dugovic C, ''et al.'' |title=Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist |journal=Br. J. Pharmacol. |volume=143 |issue=5 |pages=649–61 |date=November 2004 |pmid=15466448 |pmc=1575430 |doi=10.1038/sj.bjp.0705964}}</ref> and has been suggested as a possible treatment for memory defects associated with [[epilepsy]].<ref>Jia F, Kato M, Dai H, Xu A, Okuda T, Sakurai E, Okamura N, Lovenberg TW, Barbier A, Carruthers NI, Iinuma K, Yanai K. Effects of histamine H(3) antagonists and donepezil on learning and mnemonic deficits induced by pentylenetetrazol kindling in weanling mice. ''Neuropharmacology''. 2006 Mar;50(4):404-11. PMID 16310812</ref> JNJ-5207852 itself did not progress to clinical development due to poor pharmacokinetic characteristics, but the related compound [[JNJ-17216498]] is currently in Phase II clinical trials for the treatment of [[narcolepsy]].<ref name="pmid18469850">{{cite journal |author=Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD |title=The histamine H3 receptor: an attractive target for the treatment of cognitive disorders |journal=Br. J. Pharmacol. |volume=154 |issue=6 |pages=1166–81 |date=July 2008 |pmid=18469850 |doi=10.1038/bjp.2008.147 |pmc=2483387}}</ref>
+[[File:JNJ-5207852.svg|thumb|right|Chemical structure of JNJ-5207852]]
-==References==
+'''JNJ-5207852''' is a chemical compound that acts as a potent and selective antagonist of the [[5-HT2A receptor]], a subtype of the [[serotonin receptor]]. It was developed by [[Johnson & Johnson]] for potential use in the treatment of various [[psychiatric disorders]], including [[schizophrenia]] and [[depression]].
-{{reflist}}
-{{Histaminergics}}
+== Mechanism of Action ==
-[[Category:H3 receptor antagonists]]
+JNJ-5207852 functions primarily by blocking the activity of the 5-HT2A receptor. The 5-HT2A receptor is a [[G protein-coupled receptor]] (GPCR) that is activated by the neurotransmitter [[serotonin]]. By inhibiting this receptor, JNJ-5207852 can modulate the effects of serotonin in the brain, which is thought to be beneficial in treating disorders characterized by dysregulated serotonin signaling.
-[[Category:Piperidines]]
-[[Category:Phenol ethers]]
-[[Category:Johnson & Johnson]]
+== Pharmacological Properties ==
-{{pharma-stub}}
+JNJ-5207852 is known for its high affinity and selectivity for the 5-HT2A receptor, which minimizes its interaction with other serotonin receptor subtypes. This selectivity is crucial for reducing potential side effects associated with non-specific serotonin receptor antagonism.
-{{organic-compound-stub}}
+== Potential Therapeutic Uses ==
+The primary therapeutic interest in JNJ-5207852 lies in its potential to treat [[schizophrenia]], a complex psychiatric disorder characterized by symptoms such as [[hallucinations]], [[delusions]], and cognitive impairments. By antagonizing the 5-HT2A receptor, JNJ-5207852 may help alleviate some of these symptoms.
+Additionally, there is interest in exploring its use in treating [[major depressive disorder]], where it may help improve mood and cognitive function by modulating serotonin pathways.
+== Research and Development ==
+Research into JNJ-5207852 has primarily focused on its pharmacological profile and its effects in preclinical models of psychiatric disorders. Studies have demonstrated its efficacy in reducing symptoms associated with schizophrenia in animal models, paving the way for potential clinical trials in humans.
+== Related Pages ==
+* [[5-HT2A receptor]]
+* [[Serotonin]]
+* [[Schizophrenia]]
+* [[Major depressive disorder]]
+* [[G protein-coupled receptor]]
+[[Category:Pharmacology]]
+[[Category:Serotonin receptor antagonists]]
+[[Category:Experimental drugs]]